Evidence map›Paper›PMID 35399681›Full record

ArticleFrontiers in nutrition2022

Classification of the Occurrence of Dyslipidemia Based on Gut Bacteria Related to Barley Intake.

Satoko Maruyama, Tsubasa Matsuoka, Koji Hosomi, Jonguk Park, Mao Nishimura, Haruka Murakami, Kana Konishi, Motohiko Miyachi, Hitoshi Kawashima, Kenji Mizuguchi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Satoko MaruyamaResearch and Development Department, Hakubaku Co., Ltd., Yamanashi, Japan.
Tsubasa MatsuokaResearch and Development Department, Hakubaku Co., Ltd., Yamanashi, Japan.
Koji HosomiLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Jonguk ParkArtificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Mao NishimuraResearch and Development Department, Hakubaku Co., Ltd., Yamanashi, Japan.
Haruka MurakamiDepartment of Physical Activity Research, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo, Japan.
Kana KonishiDepartment of Physical Activity Research, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo, Japan.
Motohiko MiyachiDepartment of Physical Activity Research, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo, Japan.
Hitoshi KawashimaArtificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Kenji MizuguchiArtificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Toshiki KobayashiResearch and Development Department, Hakubaku Co., Ltd., Yamanashi, Japan.
Tadao OokaDepartment of Health Sciences, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Zentaro YamagataDepartment of Health Sciences, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Jun KunisawaLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
National Institute of Biomedical Innovation, Health and Nutrition · JPUniversity of Yamanashi · JPOsaka University · JPProtein Research Foundation · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Barley is a grain rich in β-glucan, a soluble dietary fiber, and its consumption can help maintain good health and reduce the risk of metabolic disorders, such as dyslipidemia. However, the effect of barley intake on the risk of dyslipidemia has been found to vary among individuals. Differences in gut bacteria among individuals may be a determining factor since dietary fiber is metabolized by gut bacteria and then converted into short-chain fatty acids with physiological functions that reduce the risk of dyslipidemia. This study examined whether gut bacteria explained individual differences in the effects of barley intake on dyslipidemia using data from a cross-sectional study. In this study, participants with high barley intake and no dyslipidemia were labeled as "responders" to the reduced risk of dyslipidemia based on their barley intake and their gut bacteria. The results of the 16S rRNA gene sequencing showed that the fecal samples of responders (

Indexed as

barleydyslipidemiagut bacteriamachine learningresponder

Identifiers

PMID35399681
PMCPMC8988889
OpenAlexW4220684877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.